Kidney Cancer

Research from the 2021 International Kidney Cancer Symposium North America identified prognostic value in cell cycle proliferation and epithelial-mesenchymal transition pathway scores in clear cell renal cell carcinoma in predicting survival and recurrence.

A notable association has been identified between non-clear cell renal cell carcinoma and proliferative disease.

Brian I. Rini, MD, detailed the focus, goals, and key end points of a 3-arm, phase 3 trial comparing MK-1308A or belzutifan plus lenvatinib and pembrolizumab to the control of lenvatinib and pembrolizumab alone to treat patients with advanced clear cell renal cell carcinoma.

Patient with advanced renal cell carcinoma who were treated with nivolumab and ipilimumab experienced a long-term survival benefit that was superior to sunitinib.

Treatment with sunitinib resulted in improved efficacy results in the FIRSTMAPPP trial for patients with malignant pheochromocytoma and paraganglioma.

Patients with intermediate- and poor-risk metastatic renal cell carcinoma experienced promising responses after being treated with perioperative cabozantinib.

Those with advanced renal cell carcinoma whose disease was previously treated experienced long-lasting and robust overall survival following treatment with cabozantinib.

Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.

Patients with VHL-mutant and wild type clear cell renal cell carcinoma may have comparable clinical characteristics, although other genetic alterations may be at play.

A lack of understanding, communication, and more was expressed among both patients and caregivers regarding a subtype of kidney cancer.

Patients with advanced renal cell carcinoma experienced improvements in both progression-free and overall survival after being treated with first-line immunotherapy vs sunitinib, although the benefit is yet to be determined in those with favorable-risk disease.

Further results from the KEYNOTE-426 trial continue to support the combination of pembrolizumab plus axitinib in patients with clear cell renal cell carcinoma.

The combination of pembrolizumab plus lenvatinib received approval by the FDA in the first-line setting for patients with advanced renal cell carcinoma following the results of the phase 3 CLEAR trial.

A priority review to a biologics license application has been granted by the FDA for adjuvant pembrolizumab in certain populations of patients with renal cell carcinoma who have undergone surgery.

The combination of lenvatinib plus pembrolizumab showed antitumor activity and a manageable safety profile for treatment-naïve or previously treated patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD, spoke with CancerNetwork® about emerging second-line therapies as the paradigm of first-line treatment evolves for patients with metastatic clear cell renal cell carcinoma.

Robert A. Figlin, MD, highlights toxicities that patients with renal cell carcinoma experience while on cabozantinib.

New findings indicate that historically underserved patient populations with renal cell carcinoma are more likely to receive non–guidance-based treatment.

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma.

Benjamin A. Teply, MD, considers the optimal treatment of renal cell carcinoma in a peer perspective accompanying an article by Tiffany Y. Shaw, MD, and colleagues.

Motzer discussed time to deterioration end points for patients with advanced renal cell carcinoma treated with pembrolizumab and lenvatinib in the first-line setting.

In recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase inhibitors (TKIs) and immunotherapy. This has led to a need to address standard-of-care treatment in the second-line setting.

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss results of the CANTATA trial of cabozantinib with or without telaglenastat.

Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.